Built with biopharma, for biopharma.

Get your IND submission ready in weeks, not months.

Filyn delivers a secure, purpose-built, AI-native workspace that streamlines IND preparation — reducing timelines, minimizing rework, and getting therapies to patients faster.

Friction in IND Preparation

  • Siloed authoring across functional teams and systems
  • Version churn with overlapping reviews and conflicting edits
  • Content gaps or inconsistencies identified late in the process
  • Manual effort required to package and secure sign-offs for submission

Our Early Focus

  • Consistency across teams — aligning content and reducing silos
  • Control over versions — keeping reviews structured and traceable
  • Readiness confidence — identifying issues before they create delays
  • Submission alignment — outputs structured to meet regulatory standards

Filyn starts with IND — the pivotal gateway to first-in-human trials. From this starting point, our technology is designed to grow into NDA, BLA, and global filings — building toward the future of AI-native regulatory infrastructure.

Early Access Capabilities

Compliance in business concept. Person use smartphone with compliance icon on virtual screen

AI Drafting Assistant

Generates structured baseline content, providing authors with a consistent starting point and enabling experts to focus on review and scientific judgment.

Data analytics and insights powered by big data and artificial intelligence technologies. Data mining, filtering, sorting, clustering and computing by AI for business analytics dashboard with charts.

Completeness Check

Performs automated checks across documents to flag missing sections or inconsistencies earlier in the process, helping reduce late rework.

Compliance in business concept. Laws concept. Enforce laws, regulations and standards. requirements, audit diagram on virtual screen.

Collaboration Hub

A secure, eCTD-aligned workspace where teams manage versions, comments, and sign-offs in one place, maintaining traceability and control.

These capabilities are offered in early access for evaluation within defined IND sections. All outputs require expert review and validation. We are inviting partners to join us in shaping the platform as it evolves.

Why Participate Now

Explore Ways to Ease Submission Workload

Early access lets you see how AI-assisted drafting might reduce repetitive authoring and reconciliation, while keeping expert judgment central.

Evaluate Tools for Earlier Issue Detection

Pilot automated checks designed to surface missing contents sooner, with all findings subject to your review and validation.

Prepare for Evolving Regulator Expectations

Gain familiarity with AI-supported approaches that regulators are beginning to explore, in a controlled, evaluation-only setting.

Our Approach and Edge

Practical and credible for today’s INDs. Scalable and defensible as tomorrow’s regulatory infrastructure.
Smart law, legal advice icons and astute lawyer working tools in lawyers office

Shaped by Regulatory Reality

Co-developed with regulatory teams and former FDA reviewers, so every feature maps to real submission workflows.

Compliance in business concept. Laws concept. Enforce laws, regulations and standards. requirements, audit diagram on virtual screen.

Compliance by Design

Built around eCTD standards with permissions, version locks, sign-offs, and validation engineered for credibility and adoption.

Controlling AI Technology

AI with Guardrails

Specialized AI agents draft, check, and organize — always under human oversight, with audit trails and full explainability.

AI-Driven Workflow, Automating Business Reports with KPIs and Data Management Analytics, Big Data Integration, and Predictive Insights. Businessman touching Virtual Screen with Decision-Making Tech.

Compounding Advantages

Each expert edits enrich a proprietary regulatory corpus, creating a defensible data moat that grows with every filing.